SciBase announces distribution agreement with Lischke Medizintechnik in Germany
SciBase, a leader in skin cancer detection technology, announced today that it has entered into a distribution agreement with Lischke Medizintechnik for distribution of Nevisense electrode disposable components in Germany.
Nevisense is a point of care device used to support clinicians to accurately detect malignant melanoma. A disposable component is used in combination with the device which has to be changed between patients. In order to provide clinicians in Germany with easier access to this component Scibase has entered into a cooperation with Lichke Medizintechnik, a well recognized supplier to dermatology clinics in Germany.
“Lischke Medizintechnik’s reputation and established relations among dermatologists in Germany makes them an ideal partner to Scibase – strengthening our business position as well as making ordering of our products easier for the German customers”says Anders Lundqvist, CEO of SciBase.,
“Lischke Medizintechnik has a long history of supplying devices and supplies for the dermatology practitioners in Germany”, says Olaf Lischke, CEO of Lischke Medizintechnik. “We are therefore very happy to include this product in our offering to German dermatologists, as we believe it has the potential to support clinicians in early detection of malignant melanoma.”
Lischke Medizintechnik, with head office in Bochum, Germany, is a leading independent distributor of devices in dermatology in Germany.
About Lischke Medizintechnik
Founded by Klaus P. Lischke in 1994, now family run in 2nd generation by his daughter-in-law Claudia Lischke-Arzt and his son Olaf Lischke, Lischke Medizintechnik is a supplier of medical equipment for dermatologists in and around Germany. The product portfolio includes dermatoscopes and other optical equipment, cryo equipment, skin analysis systems, electrosurgical units and software.
About SciBase
Founded in 1998, SciBase is a Swedish medical technology company that has developed a unique diagnostic support tool for accurate detection of malignant melanoma. Following 20 years of academic research at Karolinska Institutet Stockholm, the ability of the Nevisense point-of-care device to accurately detect melanoma is now proven in the world’s largest prospective study of its kind.
For more information, please contact:
Anders Lundqvist, CEO, SciBaseAB, +46 732 06 98 08
Per Svedenhag, Director Clinical & Commercial Operations, SciBaseAB, +46 732 06 98 01